Axiron Testosterone Topical Solution: Side Effects, Uses, Dosage, Interactions, Warnings

Two patients (3%) had adverse reactions that led to discontinuation of treatment during the period from Day 120 to Day 180. AXIRON (testosterone) topical solution is available as a metered-dose pump containing 110 mL of solution. For patients prescribed the 90 mg dose of testosterone, the procedure is the same, but three applications are required. The application site and dose of AXIRON are not interchangeable with other topical testosterone products. The recommended starting dose of AXIRON (testosterone) topical solution is 60 mg of testosterone (2 pump or 2 twist actuations) applied once daily. Our Axiron (testosterone) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. Pregnant and breast-feeding women must avoid skin contact with application sites on men.
Testosterone treatment for reasons other than possible improvement of sexual dysfunction may not be recommended. Decline of testosterone production with age has led to interest in testosterone supplementation. In 2023, it was the 119th most commonly prescribed medication in the United States, with more than 5 million prescriptions.
What are the possible side effects of AXIRON? Women who are pregnant or who may become pregnant should avoid contact with the area of skin where AXIRON has been applied. AXIRON is not meant for use in women. Never give AXIRON to anyone else, even if they have the same symptoms you have. AXIRON is a controlled substance (CIII) because it contains testosterone that can be a target for people who abuse prescription medicines. Your healthcare provider will test your blood before you start and while you are taking AXIRON.
Exogenous testosterone may cause suppression of spermatogenesis in men, leading to, in some cases, reversible infertility. In February 2025, the US Food and Drug Administration (FDA) specified label changes for products containing testosterone. Another approach being investigated is the detection of the administered form of testosterone, usually an ester, in hair. A number of methods for detecting testosterone use by athletes have been employed, most based on a urine test. This has proven contentious, with the Court of Arbitration for Sport suspending the IAAF policy due to insufficient evidence of a link between high androgen levels and improved athletic performance. The most common route of administration for testosterone is by intramuscular injection. Testosterone has been marketed for use by oral, sublingual, buccal, intranasal, transdermal (patches), topical (gels), intramuscular (injection), and subcutaneous (implant) administration.
Shortly thereafter, in 1937, testosterone first became commercially available as a pharmaceutical drug in the form of pellets and then in ester form for intramuscular injection as the relatively short-acting testosterone propionate. Prominent examples include nandrolone (19-nortestosterone), metandienone (17α-methyl-δ1-testosterone), and stanozolol (a 17α-alkylated derivative of DHT). Unlike testosterone ester and ether prodrugs however, these prohormones are only weakly androgenic/anabolic.
In addition to ester and ether prodrugs, androgen prohormones or precursors of testosterone, such as dehydroepiandrosterone (DHEA), androstenediol, and androstenedione, exist as well, and convert into testosterone to variable extents upon oral ingestion. Another C17β ether prodrug of testosterone order, silandrone, also exists but was never marketed, and is notable in that it is orally active. A C17β ether prodrug of testosterone, cloxotestosterone acetate, has also been marketed, although it is little known and is used very rarely or no longer. Major testosterone esters include testosterone cypionate, testosterone enanthate, testosterone propionate, and testosterone undecanoate. The ARs are expressed widely throughout the body, including in the penis, testicles, epididymides, prostate gland, seminal vesicles, fat, skin, bone, bone marrow, muscle, larynx, heart, liver, kidneys, pituitary gland, hypothalamus, and elsewhere throughout the brain. In contrast to the case of testosterone, such potentiation occurs to a reduced extent or not at all with most synthetic AAS (as well as with DHT), and this is primarily responsible for the dissociation of anabolic and androgenic effects with these agents.
Keep all medications away from children and pets. Use your next dose at the regular time. If it is near the time of the next dose, skip the missed dose. If you miss a dose, use it as soon as you remember. A different medication may be necessary in that case. This medication has been prescribed for your current condition only. Do not share this medication with others.
Evaluate patients who report symptoms of pain, edema, warmth and erythema in the lower extremity for DVT and those who present with acute shortness of breath for PE. It would be appropriate to re-evaluate the hematocrit 3 to 6 months after starting testosterone treatment, and then annually. Check hematocrit prior to initiating testosterone treatment. Increases in hematocrit, reflective of increases in red blood cell mass, may require lowering or discontinuation of purchase testosterone. Children and women should avoid contact with unwashed or unclothed application sites in men using AXIRON see DOSAGE AND ADMINISTRATION , Use In Specific Populations and CLINICAL PHARMACOLOGY. In most cases, https://telegra.ph/How-to-Legally-Buy-Testosterone-Online-A-Z-Guide-03-22 these signs and symptoms regressed with removal of the exposure to testosterone.
During the 120 day trial one patient discontinued treatment because of affect lability/anger which was considered possibly related to AXIRON administration. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. One actuation delivers 30 mg of testosterone in 1.5 mL of solution. While interpersonal testosterone transfer can occur with a T-shirt on, it has been shown that transfer can be substantially reduced by wearing a T-shirt and the majority of residual testosterone is removed from the skin surface by washing with soap and water.